RAC - Charts & Price Action, page-1452

I am very happy reading your posts .

I really , very much hope that this means , that your doctor acquaintance ? — is / has used Bisantrene for their AML patients ??
( In Australia - if so, this can only be currently )

Truly thankful if this is so .

Do not concern-
I only want Bisantrene to have the chance to be back into treatment use , & be used in a very regular treatment way , in chemotherapy if it can save patients lives more, or cause them less harm and suffering.

Totally different although a related thing to traditional chemotherapy treatment use :-
*The FTO protein factor - is a patient specific ,individually significant factor ; which is fantastic in how it is now recognised .

The FTO protein is important and now being understood as a protein that if it is higher and over- expressed, is of significance for Bisantrene —as clearly in lab it has shown the most compellingly high specificity against this for anyone who is susceptible to their cancer ‘because’ of increased FTO Protein .
(*COH Study, 2020 results — Over 250000 drugs , agents tested against the FTO Protein specifically . )
As an important now recognised important cancer treatment target where it is relevant—the FTO protein :
* Bisantrene the No 1 !! out of over 250000 drugs tested specifically against the FTO Protein, was the best inhibitor .

“Genetics” — we coined a new phrase at work due to sentient health events too often observed .
So often , medical history and health events express as we see it , and arrive “like a freight train ... right on time” , at a certain age or in ‘type ‘of event. ( the ‘same as the parent’ )

Nature not nurture .

Not being negative , only something to understand.
Every individual is unique . And more is being understood all of the time .

With respect to the FTO Protein - for some people this is very relevant for . And it is not uncommon .
It is relevant for AML also .

*The FTO Protein expression , and it’s increasing — is very much associated with quite a number of cancers & is associated strongly with these cancers occurrence, but more importantly is associated with high morbidity .
So eg. AML is a harder to treat Leukaemia.
Many AML leukaemias are very difficult to treat - and there is high , terrible morbidity .
*There is a huge amount of research , globally , to seek to treat AML better , and to save more people’s lives .

AML , a subset , (?? the higher morbidity ones) - might be due to being associated with higher FTO Protein in the individual .
Likely this can be of importance - and if so , is a “why” for why Bisantrene can achieve a CR ,” remission” , where nothing else has fully knocked out the cancer or where these is nothing more standard -of -care wise that can be used and Bisantrene can be tried.

Anyway , I just want to see it back in the clinical armamentarium.

Without doubt in the greater picture — more .,and better , and moretargeted drug agents are very much needed in Oncology.